Skip to main content

Table 2 Number of references including specific preference-related term in the different guideline cases

From: The use of research evidence on patient preferences in pharmaceutical coverage decisions and clinical practice guideline development: exploratory study into current state of play and potential barriers

  England & Wales GAD case Scotland CHF case Netherlands Prostate CA case France CHF case Germany Depression case England & Wales RA case Scotland RA case Netherlands RA case France RA case Germany RA case Total
Value 0 0 0 0 0 0 0 0 0 0 0
Utilities 1 0 0 0 0 0 0 2 0 1 4
Preference 3 1 5 0 0 2 1 0 0 0 12
View 1 0 1 0 0 1 0 0 0 0 3
Goal 0 0 0 0 0 0 0 0 0 0 0
Belief 3 0 0 0 0 1 0 0 0 0 4
Expectation 0 0 0 0 0 0 0 0 0 0 0
Experience 2 0 5 0 0 2 0 0 0 0 9
Satisfaction 0 0 0 0 0 3 0 1 0 0 4
Health related quality of life 3 1 3 0 1 9 0 2 2 1 22
Quality of life 4 3 18 0 3 4 0 2 0 1 35
Concern 0 1 2 0 0 0 0 0 0 0 3
Desire 0 0 0 0 0 0 0 0 0 0 0
Perspective 2 0 4 0 3 2 0 4 1 0 16
Attitude 0 0 0 0 1 0 0 0 0 0 1
Perception 1 1 0 0 0 1 0 0 0 0 3
Well being 1 1 1 0 1 4 0 1 1 1 11
Need (for) 5 0 9 0 4 2 0 0 0 0 20
Choice 0 0 0 0 0 2 0 0 0 1 3
PRO 0 0 0 0 0 1 0 0 0 3 4
  1. GAD: generalised anxiety disorder; CA: carcinoma; RA: Rheumatoid Arthritis.